Ok ? Har liste her foran meg datert 31.10.2022
Her har Sundt 200000 aksjer.
edit: solgte kanskje etter at listen jeg har ble skrevet ut ??
De solgte 400K 20.okt
stemmer
Tone Kvåle holder fortsatt sine aksjer ser jeg … 
Tone kommer fra en tradisjonsrik skipsfartsfamilie. Der lærer man at gjengen på broen er de siste som skal forlate skuta.
Tone hentet 500 mill på kurs 110 NOK og rømmer fortsatt ikke båten. Noe ærverdig over det også.
1 Like
Sundt er ute.
Mannen bak Selaco AS hadde vel en rolle i podcast “Aksjesladder” fra den 14. oktober hvor han på slutten sier at han har tatt et bet. Siden da har han først solgt seg ut for så å kjøpe en god del (på listene) mot slutten av oktober og begynnelsen av november.
I podcasten har han et regnestykke for at dette bør kunne være et bra bet.
Det er mange som bare sitter på topp 50. Noen er ute og noen kommet til. En av de, aner ikke hvem det er, er Jon Magne Asmyr som har akkumulert 1M aksjer i løpet av høsten og gjennom det er topp 10.
Han økte med 300 000 aksjer på dagens liste. Er topp 5 nå med 1,3 mill aksjer.
2 Likes
Det kaller jeg overbevisning.
Nordic Nanovector ASA (OSE: NANOV) (“Nordic Nanovector” or the “Company”) announces the progress it has made in designing and developing a portfolio of novel and potent humanized anti-CD37 monoclonal antibodies with potential for treating B-cell malignancies or B-cell-driven autoimmune disorders.
Details of the Company’s progress in engineering this portfolio are included in two abstracts published today for presentation as posters at the 64[th] American Society of Hematology (ASH) Annual Meeting & Exposition (10-13 December 2022 in New Orleans, LA, USA). The abstracts will also be published online in a November supplemental issue of Blood, published by The American Society of Hematology.
The abstracts describe how, through antibody engineering, Nordic Nanovector has developed several humanized anti-CD37 monoclonal antibodies and demonstrated in preclinical studies their enhanced effector mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and longer half-life in the blood.
CD37 is a protein abundant on the surface of B cells but absent in haematopoietic stem cells and plasma cells. Its expression pattern makes it attractive as a therapeutic target for B-cell malignancies, including non-Hodgkin lymphomas and chronic lymphocytic Leukemia and for B-cell-driven autoimmune disorders, especially where an alternative to standard anti-CD20 immunotherapy is sought.
Jostein Dahle, Co-founder and CSO of Nordic Nanovector, commented: “We are pleased to present at ASH the initial findings from our preclinical studies with our novel humanized anti-CD37 antibody portfolio. These antibodies have been designed to be highly selective for CD37 on B cells and shown to be potent at depleting these cells as well as enduring in the circulation. There is a significant unmet clinical need for new therapeutic approaches for patients with B-cell-driven diseases who do not respond to anti-CD20 therapies. The encouraging preclinical results we will present at ASH support the further development of these candidates for B-cell malignancies or B-cell-driven autoimmune disorders.”
Details of the abstracts to be presented at ASH are as follows:
Abstract 1351
Abstract title: NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell Malignancies
Authors: R. Generalov et al.
Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
Date: Saturday, December 10
Presentation Time: 5:30 PM - 7:30 PM Eastern time
Location: Ernest N. Morial Convention Center, Hall D
Abstract 2679
Abstract title: B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-Life
Authors: E. Fiorito et al.
Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
Session Date: Sunday, 11 December
Presentation Time: 6:00 PM - 8:00 PM Eastern time
Location: Ernest N. Morial Convention Center, Hall D
IR enquiries
Malene Brondberg, interim CEO & CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Frazer Hall / Mark Swallow (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company’s clinical- and preclinical-stage pipeline includes:
-
Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies incorporating the beta emitter lutetium-177 to treat non-Hodgkin’s lymphoma (NHL);
-
Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the alpha-emitting radionuclide lead-212, currently being explored with partner Oranomed for chronic lymphocytic leukaemia;
-
Multiple fully humanized anti-CD37 antibodies with potential in haematological cancers and autoimmune diseases; and
-
A CD37 DOTA CAR-T cell opportunity in haematological cancers, which is being advanced via a research collaboration with the University of Pennsylvania.
8 Likes
Shit, så det er dette Jostein holder på med, blant annet.
Faktisk to stk abstracts, ikke bare en. Me like.
Good work!! 
8 Likes
Oppløftende at lyset ikke er slukket enda! 
Dette gir meg tro på at det finnes en fremtid for selskapet
9 Likes
Dette var dr.deehans bord tidligere.
TO abstracts…
what the hell…
Da fikk jeg vertfall svar på ene delen av mailen som ble sendt for en god stund siden:
"I also see on your company presentation that the pipeline now consists of several things - i.e
Multiple fully humanized anti-CD37 antibodies with different effector mechanisms for treatment of haematological cancers and autoimmune diseases;
This was Dr.Deehans presentation during the R&D day - and we were promised more information on this during 1h22. Since the presentation explicitly tells us that Nordic Nanovector now has “Multiple…” hzab, do you mind explaining why the markets have not been informed of this development?"
Touché motherfudger.
4 Likes
De to abstraktene :
https://ash.confex.com/ash/2022/webprogram/Paper166275.html
Conclusion: These encouraging preclinical results support further development of NNV024 as a potential therapeutic mAb candidate for the treatment of B-cell malignancies and B-cell driven autoimmune disorders.
https://ash.confex.com/ash/2022/webprogram/Paper159382.html
Conclusions: Taken together, the humanized and Fc-engineered anti-CD37 antibodies show potent effector functions, favorable pharmacokinetic properties and in vivo therapeutic efficacy. As such, the designed CD37 antibodies should be attractive modalities in targeted treatment of B cell malignancies, such as NHL, including lymphomas non-responding to anti-CD20 treatments, but also potentially for B-cell driven autoimmune disorders.
1 Like
… 4,00; let’s go
2 Likes
Ingen som kjenner på litt FOMO her nå 
2 Likes
Risikoen ligger på oppsiden!
2 Likes
Opp på høyt volum, faller tilbake på lavt volum. Lett når kjøpsordrene i markedet ikke er av betydelig størrelse. Vært gøy med en close over 1.50, men algoene vil det annerledes.
Men har vi ikke fått han fyren på laget da ? han som lurte disse algoene
Han solgte nå (skrev det på XI).